Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.60 |
| ▸ | DGKA | P23743 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PAM | P19021 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889203 | 1.00 | NAAA (0.60) | NAAADGKAHTR2CMAPTRAD52 | |
| SCHEMBL889196 | 1.00 | NAAA (0.60) | NAAADGKAHTR2CMAPTRAD52 | |
| SCHEMBL889159 | 1.00 | NAAA (0.60) | NAAADGKAHTR2CMAPTRAD52 | |
| SCHEMBL6439025 | 1.00 | NAAA (0.60) | NAAADGKAHTR2CMAPTRAD52 | |
| SCHEMBL889135 | 1.00 | NAAA (0.60) | NAAADGKAHTR2CMAPTRAD52 | |
| SCHEMBL889166 | 1.00 | NAAA (0.60) | NAAADGKAHTR2CMAPTRAD52 | |
| SCHEMBL889149 | 1.00 | NAAA (0.60) | NAAADGKAHTR2CMAPTRAD52 | |
| SCHEMBL9151467 | 1.00 | NAAA (0.60) | NAAADGKAHTR2CMAPTRAD52 | |
| SCHEMBL889284 | 1.00 | NAAA (0.60) | NAAADGKAHTR2CMAPTRAD52 | |
| SCHEMBL889133 | 1.00 | NAAA (0.60) | NAAADGKAHTR2CMAPTRAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583177-A1 | METHOD OF MANUFACTURING ELECTRODE, COMPOSITE ELECTRODE, ELECTROCHEMICAL ELEMENT, AND APPARATUS FOR MANUFACTURING ELECTRODE | Ricoh Company, Ltd. (JP) | 2025-07-09 | — | — | EP | disclosed |
| EP-4362128-A1 | LIQUID COMPOSITION, METHOD FOR PRODUCING LIQUID COMPOSITION, ELECTRODE, ELECTRODE PRODUCTION APPARATUS, AND METHOD FOR PRODUCING ELECTRODE | Ricoh Company, Ltd. (JP) | 2024-05-01 | — | — | EP | disclosed |
| US-20160009657-A1 | AMINE-CONTAINING LIPIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-01-14 | — | — | US | disclosed |
| US-9006487-B2 | Amine-containing lipids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2476756-A1 | Amine-containing lipids and uses thereof | Massachusetts Institute of Technology (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| WO-2009097332-A2 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | FCGRT, MYD88, C3AR1 | NAAA 789/4885DGKA 1291/4885HTR2C 978/4885 |
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | PHOSPHO1, SGMS1, APOB | NAAA 625/4885DGKA 2922/4885HTR2C 2992/4885 |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | PHOSPHO1, CHMP4B, SGMS1 | NAAA 78/4885DGKA 1692/4885HTR2C 2983/4885 |
| US-20160009657-A1 | AMINE-CONTAINING LIPIDS AND USES THEREOF | PHOSPHO1, CHMP4B, SGMS1 | NAAA 78/4885DGKA 1692/4885HTR2C 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.